Alector Inc

Despite the mid-June Bearish Exhaustion bounce, ALEC remains in a Stage 4 decline with both long- and medium-term downtrends intact. The exhaustion pattern indicates only a potential counter-trend bounce, not a sustained reversal. Short-term momentum above the 9/21 EMAs improves timing for a sell entry but price remains below key 50- and 200-day DMAs. As a result, medium-term bias stays bearish and sell-side execution should be deferred into resistance zones around the declining 50 DMA and prior support, anticipating rejection.

• ↑FDA breakthrough therapy for latosinamab underscores regulatory support
• ↑$503.3M cash runway covers operations until H2 2027
• ↓GSK ended neuroscience collaboration, eroding partner confidence